Newsroom

HYDERABAD, India--(BUSINESS WIRE)--Tanla today announced a major impact milestone for Wisely Ai, following an impact celebration event hosted by Indosat Ooredoo Hutchison in Indonesia....

PALO ALTO, Calif.--(BUSINESS WIRE)--Honda Motor Co., Ltd. and Mythic announce a joint development agreement in which Honda R&D Co. Ltd., the R&D subsidiary of Honda, will license Mythic’s Analog Processing Unit (APU) technology and the companies will co-develop an automotive-grade AI SOC for deployment in Honda’s next-generation software-defined vehicles (SDVs) by the late 2020s/early 2030s. In line with Honda’s safety approach, Mythic’s intelligent, ultra-efficient analog compute-in-me...

ニューオーリンズ＆ヨクネアム（イスラエル）--(BUSINESS WIRE)--（ビジネスワイヤ） -- 能動血管内デバイスのリーディングカンパニーであるラピッド・メディカル™は、DISTALS多施設共同無作為化対照試験からの最新の結果を発表しました。この試験では、中等度血管閉塞（MVO）脳卒中において、TIGERTRIEVER™ 13が内科的治療と比較して、優れた脳組織再灌流と安全性プロファイルを実現できることが示されました。この結果は、2026年国際脳卒中会議（ISC）のメイン閉会セッションで発表されました。 トップライン結果では、TIGERTRIEVER™ 13を適用した群は、薬物療法群と比較して症候性頭蓋内出血（sICH）を伴わない再灌流成功率が3倍高く、86.3%対27.7%（p < 0.001）との結果となりました。特筆すべきは、TIGERTRIEVER 13を投与された無作為化治療群では、sICHイベントが報告されなかったことです。比較においては、静脈内血栓溶解療法のみで報告されたsICH発生率は、最近の試験では2～6%と高くなっています1,2,3。 DISTAL...

LA NOUVELLE-ORLÉANS et YOKNEAM, Israël--(BUSINESS WIRE)--Rapid Medical™, entreprise leader dans le développement de dispositifs endovasculaires actifs, a annoncé aujourd'hui les résultats préliminaires de l'essai multicentrique randomisé contrôlé DISTALS. Ces résultats montrent que le dispositif TIGERTRIEVER™ 13 permet une reperfusion cérébrale supérieure et présente un excellent profil d'innocuité par rapport à la prise en charge médicale des AVC par occlusion des vaisseaux de moyen calibre (O...

NEW ORLEANS e YOKNEAM, Israele--(BUSINESS WIRE)--Rapid Medical™, un’azienda leader nello sviluppo di dispositivi endovascolari attivi, oggi ha annunciato i risultati “late-breaking” del trial clinico controllato, randomizzato e multicentrico DISTALS, che dimostrano che TIGERTRIEVER™ 13 ha ottenuto una riperfusione superiore del tessuto cerebrale, con un eccellente profilo di sicurezza, rispetto alla gestione medica nell’ictus da occlusione dei medi vasi. I risultati sono stati presentati durant...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of SunOpta Inc. (NASDAQ: STKL) to Refresco for $6.50 per share in cash. Halper Sadeh encourages SunOpta shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether SunOpta and its board of directors violated the federa...

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Richtech Robotics Inc. (“Richtech” or the “Company”) (NASDAQ:RR) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until April 3, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadli...

PARAMUS, N.J.--(BUSINESS WIRE)--Genesis Forge of Heroes officially launches Friday, Feb. 6 at 2 p.m. ET during Sean Callagy's Marketing & Sales Process Mastery Live Immersion event, introducing a breakthrough platform that eliminates the sales hiring bottleneck strangling business growth. The launch comes as companies face a critical paradox: laying off thousands of workers while desperately needing more sales capacity. Nowadays 80 percent of companies identify hiring and retaining top sale...

SAN DIEGO--(BUSINESS WIRE)--The case alleges Richtech Robotics claimed that it had a collaborative and commercial relationship with Microsoft when it did not....

美国新奥尔良与以色列约克尼姆--(BUSINESS WIRE)--(美国商业资讯)-- 领先的动脉内介入器械开发商Rapid Medical™今日公布了DISTALS多中心随机对照试验的最新突破性结果。该研究显示，在治疗中血管闭塞（MVO）卒中时，TIGERTRIEVER™ 13系统相较于保守治疗能实现更优的脑组织再灌注效果，且具有卓越的安全性。该研究成果已在2026年国际卒中大会（ISC）闭幕主会场进行展示。 顶线结果数据显示，TIGERTRIEVER™ 13组在无症状性颅内出血（sICH）情况下成功再灌注的比例是药物治疗组的3倍——86.3% vs 27.7%（pp < 0.001）。值得注意的是，接受TIGERTRIEVER 13治疗的随机治疗组未报告任何sICH事件。相比之下，仅采用静脉溶栓治疗的sICH发生率更高，在近期临床试验中报告值为2%至6%1,2,3。 “这些结果凸显了当设备和试验均针对远端卒中专门设计时所能实现的突破。”DISTALS研究首席研究员Jeffrey L. Saver医学博士表示，“DISTALS专为远端卒中量身打造，将专为细小脆弱血管设计的装置与...